Retinoblastoma (RB) is the most common intraocular malignancy in children. It is a life threatening condition but is potentially curable. RB can be hereditary or non hereditary, unilateral or bilateral (unilateral retinoblastoma, bilateral retinoblastoma, see these terms).
RB has an incidence of approximately 1/15-20,000 in Europe.
RB manifests most often in young children (90% of cases <3 years old). Early clinical signs are leukocoria and strabismus. RB is most often painless and children rarely complain of visual impairment despite its rapid progression towards loss of vision in the affected eye. Other rare signs include hypopyon, vitreous hemorrhage, non rhegmatogenous retinal detachment, neovascular glaucoma and orbital cellulitis. In later stages, rarely seen in high income countries (HIC), intracranial dissemination and hematagenous metastasis, mainly to bones and bone marrow are observed and are life-threatening. Most retinoblastomas (60%) are unilateral. Hereditary RB refers to those that arise due to a genetic predisposition (irrespective of family history); patients usually have a bilateral disease and are at increased risk to develop secondary tumors mainly sarcoma but also, pineoblastoma (see this term)/supra-sellar tumor (both named ''trilateral retinoblastoma''), glial tumor (see this term), melanoma and carcinoma.
RB is caused by inactivating mutations of both alleles of RB1 (13q14) with a high (90%) penetrance (RB risk) in most mutations. Some mutations have a low penetrance (asymptomatic carriers or unilateral RB). Monosomy 13q14 (see this term) also causes RB.
Diagnosis is mainly clinical: Indirect ophthalmoscopy supported by fundal photography. Orbital ultrasound delineates intraocular tumor and usually shows calcification. MRI imaging is used to evaluate intra / extraocular and intracranial extension. Lumbar puncture and bone marrow staging should be performed only in patients at risk of extra-ocular metastases. Genetic testing needs to be performed in all patients and their families.
Differential diagnoses, particularly in unilateral cases, include anterior chamber or lens abnormalities especially PHPV (persistence of hyperplastic vitreous), toxocariasis, X-linked retinoschisis, uveitis, medulloepithelioma, von Hippel disease, Norrie disease, retinopathy of prematurity and Coats disease (the most difficult differential diagnosis) (see these terms).
Prenatal and preimplantation genetic diagnoses are available in specialized centers in most HIC.
Patients with hereditary RB inherit RB1 mutation from a parent and thus the predisposition to RB is transmitted in an autosomal dominant manner. However, 75% of predisposed patients do not inherit the mutated RB1 from an affected parent, but might have had a de novo mutation in a parental gamete or post-zygotically.
Treatment requires a multidisciplinary highly specialized approach. In HIC, conservative treatments for at least one eye are possible in most bilateral cases and increasingly used in unilateral cases. Laser treatment alone or combined with systemic chemotherapy, cryotherapy and brachytherapy are very efficient tools; local chemotherapy delivery is currently being developed. Enucleation is still frequently used in large unilateral RB as well as in bilateral with large unilateral tumor involvement in one eye. External beam radiotherapy is only rarely used (risk of late effects, including second cancers).
Vital prognosis is excellent in HIC. Eye preservation is possible with early diagnosis. After conservative treatment, visual prognosis that depends on macular involvement is dictated by tumor location and size at diagnosis. If not treated promptly, RB may rapidly metastasize and be fatal, which is still frequent in low income countries.
Last update: May 2014
- Dr Hervé BRISSE
- Dr Laurence DESJARDINS
- Pr François DOZ
- Dr Marion GAUTHIER-VILLARS
- Dr Claude HOUDAYER
- Pr Dominique STOPPA-LYONNET